An international team, led by scientists from the University of Cambridge, has conducted a groundbreaking early-stage clinical trial injecting neural stem cells into the brains of 15 patients with secondary progressive multiple sclerosis (MS). Derived from a single donor, these stem cells demonstrated safety, tolerability, and potential long-lasting effects, suggesting a protective impact on the brain. The study addresses the urgent need for treatments targeting progressive MS, a phase where disability worsens steadily despite available therapies. The researchers observed no treatment-related deaths or serious adverse events during the 12-month follow-up, with indications of stabilized disability levels and neuroprotective effects. While acknowledging study limitations, the team sees these results as a promising step towards developing cell therapy for treating MS.
Stem Cell Therapy for Progressive MS
Join the AGEIST movement!
Sign-up for our weekly magazine.
See medical disclaimer below.
The ideas expressed here are solely the opinions of the author and are not researched or verified by AGEIST LLC, or anyone associated with AGEIST LLC. This material should not be construed as medical advice or recommendation, it is for informational use only. We encourage all readers to discuss with your qualified practitioners the relevance of the application of any of these ideas to your life. The recommendations contained herein are not intended to diagnose, treat, cure or prevent any disease. You should always consult your physician or other qualified health provider before starting any new treatment or stopping any treatment that has been prescribed for you by your physician or other qualified health provider. Please call your doctor or 911 immediately if you think you may have a medical or psychiatric emergency.